Bedrijfsoverzicht
Celularity Inc. is a regenerative and cellular medicines company dedicated to addressing aging-related and degenerative diseases through the development of off-the-shelf placental-derived allogeneic cell therapy product candidates, specifically targeting conditions such as diabetic foot ulcers and Crohn's disease. The company operates within the Healthcare sector, more specifically in the Biotechnology industry, a domain characterized by high regulatory scrutiny and significant research and development requirements to bring novel therapies to market. As of the latest available data, the company's scale is defined by a market capitalization of $36.62M, annual revenue of $40.58M, and an employee base of 123 individuals. These financial figures indicate that Celularity Inc. functions as a mid-sized entity within the biotechnology landscape, possessing a tangible revenue stream yet maintaining a relatively modest valuation relative to its operational footprint and workforce size.
Financiële gezondheid
The company reported a total revenue of $40.58M over the trailing twelve months, while simultaneously posting a net income of $-80,647,000 and an EBITDA of $-41,355,000. The substantial gap between the positive revenue figure and the significantly larger negative net income reveals a cost structure where expenses, likely driven by research, development, and general administrative costs, heavily outweigh the revenue generated from current sales. Despite the negative net income, the company generated a positive Free Cash Flow of $12.79M, which suggests a degree of financial flexibility allowing the firm to fund operations and potentially invest in growth initiatives without immediate external financing. However, the company's balance sheet shows a total cash position of $120,000 against a total debt load of $66.76M, indicating a highly leveraged position where liabilities significantly exceed liquid assets. The debt-to-equity ratio is listed as N/A, which typically occurs in capital structures where equity is negative or negligible, further highlighting the financial pressure on the balance sheet. The operating margin stands at -243.2% and the profit margin is -198.7%, figures that indicate the company is currently unprofitable on an operational and net basis, consuming a substantial portion of every dollar of revenue to cover costs. Additionally, the current ratio is 0.16, a metric that indicates the company faces severe short-term liquidity challenges as its current assets are insufficient to cover its current liabilities without external support. The Return on Equity is N/A due to the absence of positive equity, while the Return on Assets is -25.0%, a metric that reveals that the management team is currently destroying value relative to the assets employed in the business.
Waarderingsbeoordeling
The valuation metrics present a complex picture, with a trailing P/E Ratio (TTM) listed as N/A due to the lack of positive earnings, while the forward P/E is calculated at -2.23. The difference between these figures implies that the market is currently pricing in a trajectory where earnings are expected to remain negative or are not yet sufficient to generate a traditional multiple-based valuation. The price-to-book ratio is -1.78, a figure that indicates the market is pricing the company at a significant discount relative to its book value, often seen in distressed biotechnology firms or those with substantial intangible assets not fully captured on the balance sheet. Alternative valuation metrics provide further context, with a price-to-sales ratio of 0.90 and an EV/EBITDA of -2.48, suggesting that the market values the company primarily on its sales potential rather than current profitability or cash generation. Regarding price volatility and historical trading ranges, the stock has a 52-week high of $4.35 and a 52-week low of $1.01. Without the specific current share price to calculate the exact percentage, the trading range defines the maximum and minimum valuation boundaries experienced by the asset over the last year. The beta value is 0.70, which means the stock's price volatility is expected to be lower than the broader market, moving with less intensity than the overall market index during periods of fluctuation.
Growth & Income
The company's growth profile is defined by a revenue growth rate of -43.2% year-over-year, while earnings growth is listed as N/A due to the negative earnings base. The fact that revenue is contracting at such a steep rate implies that the company is facing significant challenges in sustaining its top-line sales, likely due to the commercialization phase of its cell therapy products or competitive market pressures. Since the company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute any earnings to shareholders. Instead, the company's strategy involves reinvesting all available resources, including its positive free cash flow, back into research, development, and operational continuity rather than providing income distributions to investors. The overall growth and income profile for Celularity Inc. is currently characterized by revenue contraction and a lack of dividend income, reflecting the typical characteristics of a pre-profitability biotechnology company focused on long-term therapeutic development rather than immediate financial returns.